The benefit of treatment beyond progression with immune checkpoint inhibitors: A multi-center retrospective cohort study

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021en_US
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorYekedüz, Emre
dc.contributor.authorErul, Enes
dc.contributor.authorCoşkun Yazgan, Sati
dc.contributor.authorŞahin, Taha Koray
dc.contributor.authorKarataş, Göktürk
dc.contributor.authorAksoy, Sercan
dc.contributor.authorErman, Mustafa
dc.contributor.authorYalçın, Suayib
dc.contributor.authorUrun, Yüksel
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2022-08-17T06:37:33Z
dc.date.available2022-08-17T06:37:33Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractObjective: Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation. However, real-life data on the benefit of TBP is scarce, especially from the limited resource settings and patients treated in the later lines. Therefore, we aimed to investigate the survival benefit of TBP with ICIs in patients with advanced tumors from a limited resource setting. Methods: For this multi-center retrospective cohort study, we included 282 patients treated with ICIs and had radiological progression according to RECIST 1.1 criteria. We evaluated post-progression survival according to the use of TBP (TBP and non-TBP groups) with univariate and multivariate analyses. Results: The cohort's median age was 61, and 84.4% were treated in the second or later lines. 82 (29.1%) of 282 patients continued on ICIs following the initial progression. In multivariate analyses, patients in the TBP group had improved post-progression survival compared to non-TBP (13.18 vs. 4.63 months, HR: 0.500, 95% CI: 0.349-0.717, p < 0.001). The benefit of the TBP was independent of the tumor type, treatment line, and age. Furthermore, TBP with ICIs remained associated with improved post-progression survival (HR: 0.600, 95% CI: 0.380-0.947, p = 0.028) after excluding the patients with no further treatment after progression in the non-TBP arm. Conclusions: In this study, we observed that patients receiving ICIs beyond progression had considerably longer survival. Continuation of ICIs after progression should be considered a reasonable management option for patients with advanced cancer, specifically for patients with limited alternative options.en_US
dc.identifier.citationGuven DC, Yekeduz E, Erul E, Yazgan SC, Sahin TK, Karatas G, Aksoy S, Erman M, Yalcin S, Urun Y, Kilickap S. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study. J Cancer Res Clin Oncol. 2022 Aug 12. doi: 10.1007/s00432-022-04268-8. Epub ahead of print. PMID: 35960374.en_US
dc.identifier.doi10.1007/s00432-022-04268-8en_US
dc.identifier.issn0171-5216en_US
dc.identifier.pmid35960374en_US
dc.identifier.scopus2-s2.0-85135864145en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://doi.org/10.1007/s00432-022-04268-8
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3101
dc.identifier.wosWOS:000840009500005en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Cancer Research and Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBeyond Progressionen_US
dc.subjectImmune Checkpoint Inhibitoren_US
dc.subjectImmunotherapyen_US
dc.subjectProgressive Diseaseen_US
dc.titleThe benefit of treatment beyond progression with immune checkpoint inhibitors: A multi-center retrospective cohort studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
s00432-022-04268-8.pdf
Boyut:
699.25 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu